Evidence map›Paper›PMID 39985680›Full record

ArticleJournal of gastrointestinal cancer2025

Fecal Immunochemical Testing for Colorectal Cancer Prevention in Two Public Hospitals.

Changlin Gong, Maria Teresa Medina Rojas, Maria Gabriela Rubianes Guerrero, Michail Kladas, Arameh Mousakhanian, Aarushi Sudan, Adejoke Johnson, Kimberly Cartmill, Elana Sydney, Donald P Kotler

Erratum issuedAbstract read
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Changlin Gong *Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Maria Teresa Medina Rojas *Department of Internal Medicine, Metropolitan Hospital/New York Medical College, New York, NY, USA.
Maria Gabriela Rubianes GuerreroDivision of Gastroenterology and Hepatobiliary Diseases, Metropolitan Hospital/New York Medical College, New York, NY, USA.
Michail KladasDepartment of Internal Medicine, North Central Bronx Hospital, New York, NY, USA.
Arameh MousakhanianGastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aarushi SudanGastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adejoke JohnsonDepartment of Internal Medicine, North Central Bronx Hospital, New York, NY, USA.
Kimberly CartmillDepartment of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Elana SydneyDepartment of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Donald P KotlerDivision of Gastroenterology, Jacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway South, Bronx, NY, 10461, USA. kotlerd@nychhc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionThe fecal immunochemical test (FIT) is highly effective in reducing colorectal cancer (CRC) mortality, but patient adherence to the screening process remains questionable. We present preliminary findings from a quality improvement (QI) initiative, in order to assess screening adherence and findings.

methodsAll FIT specimens in a 30-month period were retrospectively examined. Patients with positive results were included, and information was collected via electronic medical record, including QI measures such as colonoscopy completion and findings. All data were de-identified. Patients were divided into "asymptomatic group" and "symptomatic group" based on clinical manifestations. Adherence and findings were analyzed.

resultsFIT results were positive in 174 out of 2400 specimens. Colonoscopy was performed in 47.6% of all FIT-positive cases after a median interval of 5.5 (interquartile range, IQR 3-10) months, with 10% having CRC, 51.3% having adenomas, and 17.5% having advanced adenomas. Of all nine patients who had CRC, seven were in the symptomatic group. All five advanced cancers were found in the symptomatic group. Patients who actually completed colonoscopy were significantly younger than those who did not (median 61.5 years, IQR 56.5-69 years, vs. 64.5 years, IQR 59-71 years, P = 0.048). Patient-related reasons, primarily refusal, accounted for 65.9% of unperformed colonoscopies. No significant difference was found in adherence and yield between asymptomatic and symptomatic groups.

conclusionPrevalence of colorectal adenomas and cancers is high in FIT-positive patients. A substantial number of CRCs and potentially preventable CRCs must have been missed because of low adherence rate, especially in older patients. Improving adherence to CRC screening in public hospitals requires enhanced patient engagement.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerFecesOccult BloodAgedColonoscopyFemaleHospitals, PublicHumansMaleMiddle AgedPatient ComplianceQuality ImprovementRetrospective StudiesCancer educationCancer preventionColonoscopyColorectal cancerFecal immunochemical testing

Identifiers

PMID39985680
PMCPMC11846761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.